Bod discovers cannabis edibles, says clinical trial proves they work

Pic: Luis Alvarez / DigitalVision via Getty Images

Bod Australia has discovered what potheads have known for decades — edibles are an effective way to get cannabis into your body.

The company is trialing a wafer as a way to deliver cannabidiol (CBD), an element of cannabis.

People put the wafer under the tongue and it’s supposed to deliver a dose of Bod’s cannabis extract.

Bod (ASX:BDA) CEO Jo Patterson told Stockhead the Phase 1 clinical trial included getting the extract, dubbed Es315, into the wafer and then feeding it to patients to see how it moved through the body — the pharmacokinetics.

She said it succeeded on both counts: the wafer-extract combo worked and it then got CBD into people’s bloodstreams.

Bod also says it’s the first “blinded” pharmacokinetic study looking at the impact of a drug made from the full plant.

A blind study is where the patient and the doctor doesn’t know whether they’re taking the drug or a placebo.

Subscribe to our daily newsletter
Bookmark this link for small cap news
Join our small cap Facebook group
Follow us on Facebook or Twitter

While Stockhead found six other pharmacokinetic studies of cannabis featuring double-blind or higher levels of masking on the US site ClinicalTrials.gov, Ms Patterson says none has so far looked at full plant extracts.

She says a growing body of research is suggesting that the single CBD molecule is more effective when it’s taken with the other 250-odd molecules that are present in a marijuana plant.

CBD and THC, the element in cannabis that offers the psychoactive high, are just two of many molecules in a marijuana plant.

Bod’s Swiss partner Linnea SA, which supplies the extracts they use, have found a way to grow low-THC cannabis plants and an extraction process that allows them to produce a standardised CBD extract, without the THC.

Bod is testing its wafer against oils available in the Australian market.

Ms Patterson says they are looking at a low-THC extract for pain management.

Bod stock was up 8 per cent at midday to 58c.